已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

医学 安慰剂 依达拉奉 肌萎缩侧索硬化 内科学 物理医学与康复 多发性硬化 双盲 麻醉 疾病 精神科 替代医学 病理
作者
Koji Abe,Masashi Aoki,Shoji Tsuji,Yasuto Itoyama,Gen Sobue,Masanori Togo,Chikuma Hamada,Masahiko Tanaka,Makoto Akimoto,Kazue Nakamura,Fumihiro Takahashi,Kazuoki Kondo,Hiide Yoshino,Koji Abe,Masashi Aoki,Shoji Tsuji,Yasuto Itoyama,Gen Sobue,Masanori Togo,Chikuma Hamada
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (7): 505-512 被引量:1109
标识
DOI:10.1016/s1474-4422(17)30115-1
摘要

Summary

Background

In a previous phase 3 study in patients with amyotrophic lateral sclerosis (ALS), edaravone did not show a significant difference in the Revised ALS Functional Rating Scale (ALSFRS-R) score compared with placebo. Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect than did the full study population. We aimed to substantiate this post-hoc result and assess safety and efficacy of edaravone in a phase 3 trial that focused on patients with early stage ALS who met the post-hoc analysis inclusion criteria.

Methods

In this phase 3, randomised, double-blind, parallel-group study, patients aged 20–75 years with ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of ALSFRS-R, forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less were recruited from 31 hospitals in Japan. Eligible patients also had a decrease of 1–4 points in the ALSFRS-R score during a 12-week observation period before randomisation. Patients meeting all criteria were then randomly assigned 1:1 to receive 60 mg intravenous edaravone or intravenous saline placebo for 6 cycles (4 weeks per cycle with 2 weeks on, 2 weeks off) for a total treatment duration of 24 weeks. In cycle 1, the study drug or placebo was administered once per day for 14 days within a 14 day period, followed by the drug-free period. In cycle 2 and thereafter, the study drug or placebo was administered for 10 days within a 14 day period, followed by a 2 week drug-free period. Participants and investigators, including those assessing outcomes, were masked to treatment allocation. The primary efficacy outcome was the change in ALSFRS-R score from the baseline to 24 weeks (or at discontinuation if this was after the third cycle) after randomisation. The primary outcome was assessed in all patients who had received at least one treatment infusion, had at least one assessment post-baseline, and reached the end of cycle 3. For patients with missing values at the end of cycle 6, data were imputed by the last observation carried forward (LOCF) method, provided the patients had completed at least cycle 3. Safety was assessed in all patients who had received at least one treatment infusion and had at least one assessment post-baseline. This trial is registered with ClinicalTrials.gov, NCT01492686.

Findings

Between Nov 28, 2011, and Sept 3, 2014, we screened 213 patients, and enrolled 192 as potential participants. Of these, 137 patients completed the observation period: 69 were randomly assigned to receive edaravone, and 68 were randomly assigned to receive placebo. 68 patients taking edaravone and 66 taking placebo were included in the primary efficacy analysis. For the primary outcome, the change in ALSFRS-R score was −5·01 (SE 0·64) in the edavarone group and −7·50 (0·66) in the placebo group. The least-squares mean difference between groups was 2·49 (SE 0·76, 95% CI 0·99–3·98; p=0·0013) in favour of edaravone. Treatment-emergent adverse events were reported in 58 (84%) patients receiving edaravone and 57 (84%) patients receiving placebo. 11 (16%) patients taking edaravone and 16 (24%) taking placebo had serious adverse events, and one (1%) patient receiving edaravone and four (6%) patients receiving placebo had adverse events (one dysphagia in edaravone group and one dyspnoea, two respiratory disorder, and one rash in the placebo group) that led to withdrawal.

Interpretation

Edaravone showed efficacy in a small subset of people with ALS who met criteria identified in post-hoc analysis of a previous phase 3 study, showing a significantly smaller decline of ALSFRS-R score compared with placebo. There is no indication that edaravone might be effective in a wider population of patients with ALS who do not meet the criteria.

Funding

Mitsubishi Tanabe Pharma Corporation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Parker发布了新的文献求助10
刚刚
刚刚
1秒前
林夕发布了新的文献求助10
1秒前
juntang发布了新的文献求助10
1秒前
wwwf完成签到 ,获得积分10
1秒前
1秒前
zz完成签到,获得积分10
1秒前
2秒前
马浩然发布了新的文献求助20
4秒前
开放的丹南完成签到,获得积分10
4秒前
落后怜阳完成签到,获得积分10
6秒前
aki完成签到,获得积分10
8秒前
小蘑菇的应助被RUN20260921采纳,获得10
8秒前
xiaoy完成签到,获得积分10
9秒前
10秒前
周粤川完成签到 ,获得积分10
11秒前
inRe完成签到,获得积分10
12秒前
无花果的应助被lkx采纳,获得10
13秒前
14秒前
14秒前
畅销款发布了新的文献求助10
15秒前
16秒前
Parker完成签到,获得积分10
16秒前
贪玩的向薇完成签到,获得积分10
17秒前
朱雨童关注了科研通微信公众号
17秒前
18秒前
18秒前
ss完成签到 ,获得积分10
18秒前
wwf完成签到 ,获得积分10
18秒前
18秒前
FashionBoy的应助被zz采纳,获得10
18秒前
Parker发布了新的文献求助10
19秒前
molihuakai的应助被hhh采纳,获得10
19秒前
RUN20260921发布了新的文献求助10
21秒前
鸡蛋灌饼与掉渣饼完成签到,获得积分10
21秒前
21秒前
Arvin完成签到,获得积分10
22秒前
xuxiaoj完成签到 ,获得积分10
22秒前
江南脆饼发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643